Skip to main content

Market Overview

UPDATE: Canaccord Genuity Initiates Coverage on Lpath on iSONEP Potential


In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Lpath (NASDAQ: LPTN) with a Buy rating and $17.00 price target.

In the report, Canaccord Genuity noted, “We are initiating coverage of Lpath with a BUY rating and $17 price target. Lpath's iSONEP could be paradigm changing in wet AMD with $2.4B peak sales potential. The name is still under the radar, with Lpath developing a novel wet AMD treatment that targets the underlying cause, unlike current standard of care which focuses on symptom treatment.”

Lpath closed on Tuesday at $4.25.

Latest Ratings for LPTN

Apr 2014Canaccord GenuityInitiates Coverage OnBuy
Nov 2013McNicoll Lewis VlakInitiates Coverage OnBuy
Dec 2012Summer StreetInitiates Coverage OnBuy

View More Analyst Ratings for LPTN
View the Latest Analyst Ratings


Related Articles (LPTN)

View Comments and Join the Discussion!

Posted-In: Canaccord Genuity John NewmanAnalyst Color Initiation Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at